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Abstract There is great interest in drugs that are
capable of modulating multiple aging pathways,
thereby delaying the onset and progression of aging.
Effective strategies for drug development include the
repurposing of existing drugs already approved by the
FDA for human therapy. FDA approved drugs have
known mechanisms of action and have been thor-
oughly screened for safety. Although there has been
extensive scientific activity in repurposing drugs for
disease therapy, there has been little testing of these
drugs for their effects on aging. The pool of FDA
approved drugs therefore represents a large reservoir
of drug candidates with substantial potential for anti-
aging therapy. In this paper we employ
FINDSITEcomb, a powerful ligand homology model-
ing program, to identify binding partners for proteins
produced by temperature sensing genes that have been
implicated in aging. This list of drugs with potential to
modulate aging rates was then tested experimentally
for lifespan and healthspan extension using a small
invertebrate model. Three protein targets of the rotifer
Brachionus manjavacas corresponding to products of
the transient receptor potential gene 7, ribosomal
protein S6 polypeptide 2 gene, or forkhead box C
gene, were screened against a compound library
consisting of DrugBank drugs including 1347 FDA
approved, non-nutraceutical molecules. Twenty nine
drugs ranked in the top 1 % for binding to each target
were subsequently included in our experimental
analysis. Continuous exposure of rotifers to 1 lM
naproxen significantly extended rotifer mean lifespan
by 14 %. We used three endpoints to estimate rotifer
health: swimming speed (mobility proxy), reproduc-
tion (overall vitality), and mitochondria activity
(cellular senescence proxy). The natural decline in
swimming speed with aging was more gradual when
rotifers were exposed to three drugs, so that on day 6,
mean swimming speed of females was 1.19 mm/s for
naproxen (P = 0.038), 1.20 for fludarabine
(P = 0.040), 1.35 for hydralazine (P = 0.038), as
compared to 0.88 mm/s in the control. The average
reproduction of control females in the second half of
their reproductive lifespan was 1.08 per day. In
contrast, females treated with 1 lM naproxen pro-
duced 1.4 offspring per day (P = 0.027) and females
treated with 10 lM fludarabine or 1 lM hydralazine
produced 1.72 (P =\0.001) and 1.66 (P = 0.001)
offspring per day, respectively. Mitochondrial activity
naturally declines with rotifer aging, but B. manjava-
cas treated with 1 lM hydralazine or 10 lM fludara-
bine retained 49 % (P = 0.038) and 89 %
(P = 0.002) greater mitochondria activity, respec-
tively, than untreated controls. Our results demon-
strate that coupling computation to experimentation
can quickly identify new drug candidates with anti-
aging potential. Screening drugs for anti-aging effects
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using a rotifer bioassay is a powerful first step in
identifying compounds worthy of follow-up in verte-
brate models. Even if lifespan extension is not
observed, certain drugs could improve healthspan,
slowing age-dependent losses in mobility and vitality.
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Introduction
There is great interest in finding drugs capable of
extending human lifespan and healthspan (Armanios
et al. 2015). Compounds are sought that are capable of
modulating multiple aging pathways, thereby prevent-
ing a broad-spectrumof age-related diseases.Conserved
aging pathways have been identified using experimental
animal models (de Cabo et al. 2014), and some
compounds capable of delaying the onset and progres-
sion of aging have been identified; these include
spermidine, rapamycin, metformin and resveratrol.
One of the most effective strategies for drug
development is the repurposing of existing drugs that
have been approved by the FDA for human therapy
(Ashburn and Thor 2004; Pantziarka et al. 2014). FDA
approved drugs have knownmechanisms of action and
have been thoroughly screened for safety. Moreover,
many drugs have much broader ranges of action than
their licenses suggest. FDA approved drugs are likely
to have low risks, so that even small benefits might
provide an acceptable risk/benefit ratio. Although
there has been extensive commercial activity in
repurposing drugs for disease therapies (Naylor and
Schonfeld 2015), there has been little testing of these
drugs for their effects on aging. The pool of FDA
approved drugs therefore represents a large reservoir
of drug candidates with substantial potential for anti-
aging therapy. Repurposing existing drugs could have
a rapid impact on human aging if drugs can be shown
to have efficacy in slowing the progression of age-
related diseases. A strategy for rapidly finding such
drugs is to screen the suite of existing drugs compu-
tationally and then to test the predictions experimen-
tally using a short-lived invertebrate model. Promising
results can then be followed up in vertebrate and
mammalian experimental models, then confirmed in
human clinical trials.
Rotifers are experimentally tractable animal mod-
els for studying the biology of aging and representa-
tives of the supra-phylum Lophotrochozoa (Snell
2014). The brachionid rotifers that we study are about
0.4 mm long aquatic herbivores, capable of both
asexual and sexual reproduction. Their lifespan in the
laboratory at 22 C is about 2 weeks, enabling rapid
screening of many treatments using cohort life
tables (Snell et al. 2014). For example, libraries of
natural products from marine algae have been
screened for bioactivity using this rotifer model (Snare
et al. 2013). Rotifers, therefore, are useful animal
models for initial drug screening for life and health-
span extension before moving to vertebrate models.
Several rotifer genes and pathways capable of
extending lifespan have been identified (Oo et al.
2010; Ozaki et al. 2010; Snell et al. 2012, 2014b;
Gribble and Welch 2012; Snell and Johnston 2014;
Johnston and Snell 2016). Prominent among them are
nutrient sensing and stress resistance pathways. A less
appreciated pathway with substantial effects on aging
is the temperature-sensing pathway. Like many ani-
mals, rotifer lifespan is extended by exposure to
moderately lower temperatures as a result of combined
thermodynamic effects on metabolic reactions and
changes in gene expression (Johnston and Snell 2016).
These authors used a combination of life table exper-
iments, stressor challenge experiments, and RNAi
knockdown treatments to identify putative tempera-
ture sensing genes likely involved in regulating aging
rates. Four of 12 temperature-sensing genes were
identified as especially promising drug targets for life
and healthspan extension. Among these, we have
explored three rotifer temperature sensing genes and
computationally investigated drug binding partners
with the potential to modulate their expression.
Many bioinformatics and computational app
roaches for drug-protein interaction discovery have
been developed (Cavasotto andOrry 2007; Cheng et al.
2012; Gottlieb et al. 2011; Laarhoven and Marchioro
2013; Lee and Zhang 2011; von Eichborn et al. 2011;
Yamanishi et al. 2008; Yamanishi et al. 2010). Some
methods use protein sequences and a priori knowledge
of binding drugs of a protein of interest (Laarhoven and
Marchioro 2013; Yamanishi et al. 2010), whereas
docking-based approaches require high-resolution
protein structures that in most cases are not available
(Cavasotto and Orry 2007). The recently developed
FINDSITEcomb, a ligand homology modeling
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approach that has been extensively experimentally
validated (Srinivasan et al. 2014; Zhou and Skolnick
2013), has several advantages over other state-of-the-
art methods for predicting drug–protein interactions:
First, it does not require known drug interactions for a
protein target as is required by many sequence-based
methods; second, it does not require high resolution
protein structures required by docking-based methods;
third, it is much more efficient than docking-based
methods; and last, and most importantly, it has better
accuracy for ranking drug–target interactions than
other methods (Zhou and Skolnick 2013).
FINDSITEcomb has been applied in the creation of
the DR.PRODIS database (Zhou et al. 2015), which
contains comprehensive drug–protein interactions pre-
dicted for the entire Human proteome.
The hypothesis of this paper is that FINDSITEcomb
can identify drug candidates capable of life or health-
span extension, and that these can be rapidly tested
experimentally using rotifers as an animal model.
Materials and methods
FINDSITEcomb algorithm for computational
screening of FDA approved drugs
FINDSITEcomb (Zhou and Skolnick 2013) is a compu-
tational method that is capable of screening millions of
compounds on a desktop computer within a few hours.
The basic assumption of FINDSITEcomb is that similar
pockets bind to similar ligands regardless of evolution-
ary relationship. However, evolutionarily related pro-
teins have a high chance of being similar structurally.
For a given protein of unknown ligands and unknown
structure, FINDSITEcomb firstly builds a structure
model of the protein target using state-of-the-art
threading method (Skolnick et al. 2004; Zhou and Zhou
2005) and one of the best protein structure modeling
approaches, TASSER (Zhang and Skolnick 2004). The
modeled structure is subsequently employed in search-
ing against a library of pockets with experimentally
determined ligands [PDB holo structures (Bernstein
et al. 1977)] in the FINDITEfilt component (Zhou and
Skolnick 2013)—an updated version of FINDSITE
approach (Brylinski and Skolnick 2008); and is then
searched against a library of modeled structures of
proteins having experimentally determined binders but
no experimentally determined structure of the ligand–
protein complex structures [DrugBank (Wishart et al.
2006) & ChEMBL (Gaulton et al. 2012)] in the
FINDSITEX (Zhou and Skolnick 2012) component.
The ligands of the top 100 ranked pockets from PDB, of
top ranked proteins fromDrugBank&ChEMBL (called
‘‘template ligands’’) are used as ‘‘seeds’’ to search
against a compound library by a similarity-based
approach. The ligands in the compound library are
independently ranked by the three components
(FINDSITEfilt using the PDB, FINDSITEX using
DrugBank & FINDSITEX using ChEMBL) according
to their similarity to the respective template ligands. The
combined ranking gives a final prediction. In practice,
the top 1 % of ranked ligands of the compound library
are considered for further experimental test.
In this work, three protein targets of Brachionus
manjavacas corresponding to products of the transient
receptor potential gene 7 (GARS01012197.1, TRP7),
ribosomal protein S6 polypeptide 2 gene (GARS01
003002.1, S6P), or forkhead box C gene (GARS0
1006072.1, FhBC), were screened against a compound
library consisting of DrugBank drugs including 1347
FDAapproved, non-nutraceuticalmolecules. Together
with the ZINC8 (Irwin and Shoichet 2005) back-
ground, a total of 74,378 molecules are screened by
FINDSITEcomb. FDA approved drugs ranked within
the top 1 % (i.e. higher than 740th) for each target are
subsequently considered for further experimental val-
idation. Candidate drugs are listed in Table 1.
Rotifer culture
All experiments were performed using the rotifer
species B. manjavacas. This strain was originally
collected from the Azov Sea in Russia, and has been
continuously cultivated in the Snell laboratory since
1983, with resting eggs being periodically collected,
dried, and stored. Before each experiment, B. majava-
cas resting eggs were hatched in 25 mL, 15 ppt
artificial sea water (ASW, Instant Ocean) under
constant fluorescent illumination (2000 lux) at
25 C. Under these conditions, hatching begins after
18–20 h, resulting in a uniform cohort of neonates.
Hatchlings were fed the green alga Tetraselmis
suecica cultured in modified F medium (Guillard
1983) in a 560 mL chemostat with 25 % daily medium
replacement, at 25 C and constant fluorescent illu-
mination of 2000 lux. All cultures were kept in
percival I-41VL incubators to maintain stable environ-
mental conditions (Table 2).
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Table 1 Drugs predicted to bind to proteins produced by three temperature sensing Brachionus manjavacas genes, TRP7, S6P, and
FhBC
Gene Drug Ranking Mechanism Names Source
TRP7 Tadalafil 12 PDE-5 inhibitor Cialis, Adcirca Selleck Chemicals
Sildenafil 14 cGMP PDE-5 inhibitor Viagra Selleck Chemicals
Vardenafil 15 PDE-5/PDE-1 inhibitor Levitra Selleck Vhemicals
Enprofylline 16 Xanthine derivative, A1/A2 adenosine
receptor antagonist
LGM Pharma
Enoximone 20 PDE-3 inhibitor Perfan Sigma-Aldrich
Amrinone 44 PDE-3 inhibitor Inocor Sigma-Aldrich
Hydralazine 46 Smooth muscle relaxant- K-channel activator Apresoline Selleck Chemicals
Lenalidomide 47 TNF-a secretion inhibitor Revlimid Selleck Chemicals
Dyphylline 56 Xanthine derivative, adenosine receptor
antagonist, PDE inhibitor
Dilor, Lufyllin Selleck Chemicals
Pentoxifylline 68 Xanthine derivative, adenosine receptor
antagonist, PDE inhibitor
Trental Selleck Chemicals
S6P Lactulose 68 Synthetic disaccharide- promote gut bacterial
growth
Selleck Chemicals
Fludarabine 185 STAT1 activation inhibitor, DNA synthesis
inhibitor
Fludara Selleck Chemicals
Naproxen 189 COX-1/COX-1 inhibitor Aleve, Naprosyn Selleck Chemicals
Calcium gluceptate 236 Calcium supplement Selleck Chemicals
Fusidic acid 351 Bacteriostatic antibiotic–protein synthesis
inhibitor
Sigma-Aldrich
Adenosine 361 Purine nucleoside- energy transfer, signal
transduction
Selleck Chemicals
Vidarabine 362 Inhibits viral DNA synthesis Vira-A Selleck Chemicals
Ibuprofen 381 COX-1/COX-1 Inhibitor Advil, Dolgesic Selleck Chemicals
Mupirocin 408 isoleucyl tRNA synthetase inhibitor Bactroban, Centany Selleck Chemicals
c-Hydroxybutyric
acid
444 CNS depressant- GHB agonist, weak GABA
antagonist
Xyrem Controlled Subst
FhBC Lamotrigine 13 5-HT inhibitor, Na-channel blocker Lamictal Selleck Chemicals
Mexiletine 21 Na-channel inhibitor Mexitil Selleck Chemicals
L-Carnitine 29 Fatty acid transport, lipid breakdown Selleck Chemicals
Leucovorin 85 Rescues low levels of folic acid Selleck Chemicals
Fludarabine 119 STAT1 activation inhibitor, DNA synthesis
inhibitor
Fludara Selleck Chemicals
Methotrexate 178 Folic acid metabolism inhibitor Trexall Selleck Chemicals
Adenosine 218 Purine nucleoside- energy transfer, signal
transduction
Selleck Chemicals
Vidarabine 219 Inhibits viral DNA synthesis Vira-A Selleck Chemicals
Nafarelin 293 GRH analogue, LH-RH agonist, decreases LH
and FSH
Synarel Sigma-Aldrich
Colistin 320 Polymyxin antibiotic, breaks down bacterial
membranes
Xylistin, Koolistin Selleck Chemicals
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Experimental design and treatments
Full cohort life table experiments were conducted with
120 newly hatched female B. manjavacas per treat-
ment. Animals were kept in 24-well plates, with each
well containing five females in 1 mL of medium. The
medium contained 6 9 105 T. suecica cells/mL in
15 ppt ASW, any drug treatments, and 20 lM 5-flu-
oro-2-deoxyuridine (FDU), added to prevent the
hatching of asexual eggs (Snell et al. 2014b). In
experiments where drugs were dissolved in DMSO,
the control medium also contained DMSO at the same
concentration. Plates were incubated at 22 C in the
dark. Animals were checked daily and mortality was
recorded until all animals were dead. All animals were
transferred to new plates with fresh medium on day 8
to replenish their food supply, FDU, and drug
treatment.
Reproductive life table experiments were per-
formed in a similar fashion, with a few modifications.
Single females were kept in each well of 24-well plates
in 1 mL of medium, for a total of 24 females per
treatment. The medium contained 2 9 105 T. suecica
cells/mL in 15 ppt ASW and drug treatment. No FDU
was added to allow for normal egg hatching. Offspring
were produced parthenogenetically and were counted
and removed daily. The original maternal females
were transferred to new plates with fresh medium on
day 6. For reproductive screens exploring the effects
of TRP effector drugs, offspring were counted and
removed for only the first 3 days. The total number of
offspring over 3 days was used to calculate the
intrinsic population growth rate (r) for each treatment.
Survival screens
Survival screens were conducted with a cohort of 84 B.
manjavacas hatchlings per treatment and 164 hatch-
lings in the control. Animals were kept in 24-well
plates with each well containing 7 females in 1 mL of
medium. The medium contained 6 9 105 T. suecica
cells/mL in 15 ppt ASW, any drug treatments, and
20 lM FDU. Plates were incubated at 28 C in the
dark. On days 2, 4, and 6, 5 lL additional FDU (1 mg/
mL) was added to each well to prevent the hatching of
eggs. On day 6, 100 lL 6.6 9 106 cells/mL T. suecica
was added to each well to replenish food supply. On
day 8 or 10, the number of living animals was counted
and survival was recorded as average percent surviv-
ing in each well.
Estimation of rotifer swimming speed
To analyze swimming speed at different ages, rotifer
hatchlings were cultured in 6-well plates with approx-
imately 40 females per well in 5 mL medium. The
medium contained 6 9 105 T. suecica cells/mL in
15 ppt ASW, any drug treatments, and 20 lM FDU.
Plates were incubated at 22 C in the dark. Animals
were transferred to new plates with fresh medium on
day 8. On days 0, 2, 4, 6, 8, 10, and 12, 15 females from
each treatment were chosen randomly and transferred
to 5 mL 15 ppt ASW to rinse away algae cells. These
animals were then transferred to painted microscope
slides, with five females in each painted well in 12 lL
ASW. Swimming behavior in each well was recorded
for 30 s at 109magnification using a PixeLink camera
attached to a stereomicroscope. The Tracker Video
Analysis and Modeling Tool program (http://physlets.
org/tracker/) was used to track the movement of each
individual animal and calculate velocity in mm/s.
Swimming speed was estimated for 6–10 individuals
from each treatment at each time point.
Estimation of mitochondrial activity
MitoTracker Red (Invitrogen), which has an excita-
tion of 581 nm and an emission of 644 nm (Snell et al.
2014b), was used to measure mitochondrial activity.
Female rotifers were cultured in 24-well plates with
6 9 105 T. suecica cells/mL in 15 ppt ASW, appro-
priate drug treatments, and 20 lM FDU for 4 days.
Plates were incubated at 22 C in the dark. On day 4,
animals were rinsed in 15 ppt ASW for 2 h to clear
their guts and eliminate auto-fluorescent algae. After
clearing, the animals were incubated in 5 lM
MitoTracker Red in the dark for 30 min. The stain
was then rinsed away with ASW. The rotifers were
anesthetized with 1 mL club soda, fixed with 20 lL
20 % formalin, and rinsed with ASW. Images were
taken at 2009 magnification with an Alexa 568 nm
excitation filter using a Zeiss Imager Z1 microscope
with a 5 ms exposure. The average pixel intensity of
each animal was measured using ImageJ. The entire
animal was selected and measured, and the pixel
intensity of the background was subtracted. Twenty
animals were measured for each treatment.
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Statistics
Survival curves from full life tables were evaluated
using the JMP Pro 11 (SAS Institute) reliability and
survival analysis with a Wilcoxon’s test to compare
control and treatments. Eight day survival screens
were compared by ANOVA with Dunnett’s test to
compare treatments to control. A similar analysis was
used for swimming speed, MitoTracker, and
reproduction.
Results
The algorithm FINDSITEcomb (Zhou and Skolnick
2013) was used to generate a list of FDA approved
drugs that are predicted to bind to proteins produced
by the S6Ka, TRP7, and FhBC rotifer putative
temperature sensing genes. Only the top 1 % of the
strongest binders were considered. In practice this
translates to ten drugs for each gene (Table 1). We
selected four drugs to test for each gene, based on
availability, price, and mode of action. Drugs like
fludarabine that appeared on the list of two genes were
favored. We first tested the effects of selected drugs
from this list on rotifer asexual reproduction using a
3 day dose–response screen (data not shown). This
allowed us to estimate the toxicity of each drug and the
likely therapeutic dose to produce lifespan extension.
These results led us to conclude that all drugs should
be tested at concentrations of 1 and 10 lM.
As rotifers are aquatic animals, all exposures were
with drugs dissolved in the medium. The effects of 12
drugs on the survival of B. manjavacas are shown in
Fig. 1. Survival after 8 days of continuous drug
exposure was compared to either the control (dilution
medium) or a solvent control (0.2 % DMSO), if the
drug required DMSO to dissolve in the test medium.
Survival was similar in both the control and solvent
control. Exposure to two drugs putatively binding to
the TRP7 protein, tadalafil and hydralazine at 1 and
10 lM, significantly increased rotifer survival
31–43 % over the control. Similarly, 1 lM naproxen
putatively bound to the S6P protein, significantly
increasing survival 35 %. Fludarabine putatively
binds to both the S6P and FhBC proteins and
significantly increased rotifer survival by 21 and
43 % at 1 and 10 lM, respectively. Nafarelin at
10 lM putatively bound to the FhBC protein and
significantly increased rotifer survival by 22 %.
The results from the 8 day survival screen were
followed up in a full cohort life table experiment
(Fig. 2). Cohorts of 120 females were continuously
exposed to 1 lM hydralazine, 1 lM naproxen, or
10 lM fludarabine, and compared to survival in a no
drug control. The naproxen treatment significantly
extended rotifer mean lifespan by 14 %, whereas the
lifespans of hydralazine and fludarabine exposed
rotifers were not significantly different from controls.
One explanation for differences in the results of the
8 day survival screen and the life table experiment, is
that the former was conducted at 28 C, whereas the
latter was conducted at 22 C.
In addition to life extension, we also are interested
in drugs capable of extending rotifer healthspan. We
have developed three endpoints that estimate rotifer
health: swimming speed (mobility proxy), reproduc-
tion (overall vitality), and mitochondria activity
(cellular senescence proxy). B. manjavacas females
swim continuously throughout their life, initially at an
average of 0.84 mm/s as juveniles, increasing to
1.23 mm/s at age 2 days, followed by a decline back
to 0.86 mm by age 4 days (Fig. 3). Swimming speed
remains steady at about 0.9 mm/s through age
10 days, and then slowly declines until senescent
females stop swimming, fall to the bottom and die at
age about 14 days. When treated with naproxen,
fludarabine or hydralazine, maximum swimming
speed peaked at age 1.5 days at 1.38, 1.38 and
1.28 mm/s, respectively. The decline in swimming
speed was more gradual in the drug treatments, so that
on day 6, mean swimming speed of females was
1.19 mm/s for naproxen, 1.20 for fludarabine, 1.35 for
hydralazine, as compared to 0.88 mm/s in the control.
These differences are significant by an F-test, with P
values of 0.038–0.040. These data suggest that treat-
ment with these three drugs slows the decline in rotifer
swimming speed in older age classes.
Reproduction is an endpoint that often correlates
with female health and vitality. In toxicology tests,
rotifer reproduction typically is suppressed by toxicant
stress at lower concentrations than effects on survival
are observed (Snell and Janssen 1995). After a brief
juvenile period of 1 day, rotifer females begin asexual
reproduction and continue until age 12 days, so that
their reproductive lifespan is about 80 % of their entire
lifespan (Fig. 4). Reproduction peaks on day 4 at
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about five offspring/female/day and then gradually
declines until reproduction ceases on day 12. Their
reproductive lifespan can be divided into two halves,
days 1–5 and days 6–10. We compared the effects of
the drugs naproxen, fludarabine and hydralazine on
reproduction in the second half of the reproductive
lifespan. The rationale is that if these drugs improve
the health of females in older age classes, we might
observe higher reproductive rates. The average num-
ber of offspring produced by control females in the
second half of their reproductive lifespan was 1.08 per
day. In contrast, females treated with 1 lM naproxen
produced 1.4 offspring per day. Likewise, females
treated with 10 lM fludarabine or 1 lM hydralazine
produced 1.72 and 1.66 offspring per day, respec-
tively. All three of these reproductive rates are
significantly higher than control with P values of
0.027,\0.001, and 0.001, respectively.
The third endpoint that we used to estimate rotifer
healthspan is mitochondria activity. Using the
fluorochrome Mitotracker as a proxy for overall
mitochondrial activity, we quantified the decline in
fluorescence in older age classes. Preliminary exper-
iments indicated that declines in mitotacker fluores-
cence can be seen at age 4 days, about 1/3 of the rotifer
lifespan. B. manjavacas treated with 1 lM hydrala-
zine or 10 lM fludarabine retained 49 % (P = 0.038)
and 89 % (P = 0.002) greater mitochondria activity,
respectively, than untreated controls (Fig. 5).
Discussion
The significance of these results is that they provide a
proof of concept for coupling computation to exper-
imentation to quickly identify new drug candidates
with anti-aging potential. Exploring the pool of FDA
approved drugs significantly shortens drug develop-
ment cycles because the safety these compounds in
humans is already established (Ashburn and Thor
Fig. 1 Percent rotifers surviving after 8 days exposure to drugs putatively binding to proteins of 3 rotifer temperature-sensing genes.
Asterisks indicate treatments with significantly higher survival than controls (P\0.05). (Color figure online)
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Fig. 2 B. manjavacas survival in treatments of continuous 1
uM hydralazine, 1 lMnaproxen or 10 lMfludarabine exposure.
Proportion surviving refers to the age-specific survival from an
initial cohort of 120 rotifers. Mean, median and age in days
when 5% of the cohort remains alive is shown in the
figure legend. P refers to the probability that the survival curve
differs significantly from the control by Wilcoxon’s test. (Color
figure online)
Fig. 3 Effect of continuous exposure to 1 lM naproxen, 10 lM fludarabine, or 1 lM hydralazine on delaying the age-induced decline
of rotifer swimming speed. (Color figure online)
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Fig. 4 Effect of drugs on age-specific asexual reproduction of
B. manjavacas females. Reproductive lifespan is divided into
the first half (gray bar) and second half (yellow bar). Offspring
produced per day of the second half of the reproductive lifespan
is listed in the figure legend. P refers to the probability that
offspring production is significantly higher than control by
ANOVA and Dunnet’s test. (Color figure online)
Fig. 5 Fludarabine and hydralazine enhance mitochondrial
activity at age 4 days. Y-axis is average pixel intensity of
fluorescence at 620 nm. Asterisks indicate the probability by
ANOVA and Dunnet’s test that the treatments have higher
fluorescence than the control. (Color figure online)
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2004). Drug repurposing also reduces the cost and
associated risks typical of traditional drug discovery
(Pantziarka et al. 2014). Most drugs bind to multiple
targets (Zhou et al. 2015), opening possibilities that
they have as yet undiscovered effects beyond their
licensed targets. A sensible place to identify new
targets for novel anti-aging therapies is in the phys-
iological processes that underlie aging. Even if
lifespan extension is not observed, certain drugs could
improve healthspan, slowing age-dependent losses in
mobility and vitality. Screening drugs for anti-aging
effects using a rotifer bioassay is a powerful first step
in identifying compounds worthy of follow-up in
vertebrate models (Fig. 6).
The feasibility of structure-based drug repurposing
has been demonstrated by Taylor et al. (2014). They
identified druggable targets for the platelet collagen
receptor, GPVI, which promotes pathological throm-
bus formation through inappropriate platelet aggrega-
tion. If small molecules could be found that modulate
platelet formation with minimal side effects, the
impact of cardiovascular disease may be mitigated.
To find drugs that bind to GPVI, they used a computer
model that docked a FDA-approved drug library into
the GPVI collagen-binding site. They found that the
drugs losartan and cinanserin inhibited GPVI-medi-
ated platelet activation selectively, competitively, and
dose-dependently. Even though losartan is licensed as
an angiotensin II receptor antagonist drug used to treat
high blood pressure, it also binds to GPVI receptor.
Similarly, cinanserin is a 5-HT2A and 5-HT2C receptor
antagonist, used to treat atypical pneumonia, but also
binds to GPVI. The efficacy of these two drugs as
antiplatelet agents needs further testing, but their
potential for this new therapeutic use was rapidly
identified by computer modeling followed by exper-
imental testing on isolated human platelets.
Since many aging pathways have yet to be identi-
fied, it is sensible to screen a wide range of drugs for
anti-aging effects. A variety of drug screens have been
conducted using Caenorhabditis elegans (Collins
et al. 2006), with varying degrees of success. Evason
et al. (2005) screened 19 FDA-approved drugs and
identified ethosuximide, an anticonvulsant in humans,
which extended mean lifespan in wild-type C. elegans
by 17 %. Ethosuximide and trimethadione exposure at
Fig. 6 10-day survival screen for 5 ononetin analogs. (Color figure online)
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4 mg/mL also delayed functional declines in body
movement and pharyngeal pumping. Kumar et al.
(2016) screened 15 FDA-approved drugs for their
effects on the lifespan of C. elegans and found that
exposure to 2.4 mm of the antihypertensive drug
captopril extended lifespan 23 %. In both of these
studies, drugs with mechanisms of action thought to
impact aging pathways were chosen for screening.
Since many aging pathways remain unknown, this
approach is unavoidably biased toward pathways
already characterized. Kwok et al. (2006) described
a method to conduct a screen of 14,100 small
molecules for bioactivity and found that 308 produced
morphologically recognizable phenotypes in C. ele-
gans. Although this was an unbiased high-throughput
screen, none of these phenotypes could be related to
aging processes. The strength of using FINDSITEcomb
to prioritize drugs for screening for anti-aging effects
as we did in this study is that this algorithm provides a
ranked list of small molecules to target proteins. If one
screens the top 50 molecules, roughly 21 % will have
binding affinities in the micromolar range or better
(Srinivasan et al. 2014). Choosing drugs to screen
based on their binding properties is more likely to
produce novel hits than screening drugs based on their
putative modes of action in known aging pathways.
Work by Johnston and Snell (2016) implicated
three novel rotifer genes in the determination of
lifespan and healthspan. These observations motivated
us to screen a library of FDA drugs for compounds that
are predicted to bind to proteins produced by these
genes. Our intent was to determine whether some of
these drugs could be repurposed for anti-aging ther-
apy. Predicted binding partners were experimentally
assessed for anti-aging efficacy to identify new drug
targets. For example, the transient receptor potential
cation channel gene family (TRP) is a non-selective
calcium permeant cation channel involved in osmotic,
mechano- and thermosensitivity (Virens et al. 2004). It
regulates intracellular Ca2? levels, maintenance of
functional intercellular barriers, expression of
chemokines and cytokines related to proinflammatory
pathways in adipocytes, and production of IL-8 in
mice (Kottgen et al. 2008). Although TRPs play
several vital roles in regulating cell metabolism, they
have not been implicated in aging. Likewise, riboso-
mal protein S6 kinase alpha-1 (S6 K) is a family of
protein kinases involved with signal transduction and
the regulation of several cellular pathways (Fro¨din and
Gammeltoft 1999). In mice their putative function is to
mediate the activation of several mitogenic and stress-
induced transcription factors. These in turn mediate
cell proliferation, survival, and differentiation by
modulating mTOR signaling and repressing pro-
apoptotic function of BAD and DAPK1 proteins.
mTOR is a well known aging pathway, but the role of
S6 K in its regulation is poorly understood. Proteins
coded by forkhead box C genes are transcriptional
activators that regulate a variety of developmental
pathways in humans, including organ growth, artery
morphogenesis and blood vessel remodeling (van der
Horst and Burgering 2007). These proteins also affect
insulin-signaling pathways, but again their connection
to aging is not well understood. The significance of
this work is that these three genes have been identified
as potential targets for anti-aging drug therapy and
several candidate drugs have been experimentally
identified that are capable of extending lifespan or
healthspan in a rotifer animal model.
The FINDSITEcomb algorithm identified several
binding partners for the TRP, S6 K and FhBC proteins
and focused our attention on particular drugs.
Naproxen is a nonsteroidal anti-inflammatory drug
(NSAID) for relieving pain, fever, swelling, and
stiffness. It is a nonselective COX inhibitor, reversibly
inhibiting both the COX-1 and COX-2 enzymes (Hinz
et al. 2008). Naproxen also may have anti-viral
activity against influenza by blocking the RNA-
binding groove of viral nucleoprotein, thus preventing
the formation of ribonucleoprotein complexes (Lejal
et al. 2013). Although we do not know whether these
same mechanisms of action apply to rotifers, contin-
uous treatment with 1 lM naproxen extended rotifer
lifespan by 14 %. Fludarabine is a chemotherapy drug
used to treat hematological malignancies like chronic
lymphocytic leukemia (Rai et al. 2000). It is a purine
analog, that inhibits DNA synthesis by interfering with
ribonucleotide reductase and DNA polymerase. Expo-
sure of rotifers to 10 lM fludarabine significantly
improved reproduction and mitochondrial function in
older age classes, these two endpoints serving as
overall vitality and cellular senescence proxies,
respectively. Hydralazine is an antihypertensive drug
that relaxes smooth muscle, causing vasodilation in
arteries and arterioles (Candelaria et al. 2010). This
promotes a decrease in peripheral resistance and
lowers blood pressure. It also has therapeutic value
as a DNA methyltransferase inhibitor. Treatment of
918 Biogerontology (2016) 17:907–920
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rotifers with 1 lM hydralazine slowed the loss of
mobility (swimming speed) with aging. There has
been no prior indication that any of these three drugs
might be useful for anti-aging therapy. Our work
identified these three drugs as potentially useful for
anti-aging therapy from thousands of FDA approved
compounds. Follow up studies of the efficacy of these
drugs in slowing aging in vertebrate models is clearly
warranted. But taken as a whole, these studies
demonstrate the utility of FINDSITEcomb as a prior-
itization tool to identify repurposed FDA approved
drugs (as well as new chemical entities) that might
show promising anti-aging properties. When com-
bined with a screen in a model animal such as rotifers
promising leads can be rapidly identified which can
then be subject to subsequent testing in vertebrate
animal models.
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